{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:01:54Z","timestamp":1792677714486,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Liver biopsy is the gold-standard method for diagnosing and staging liver fibrosis, but the procedure is invasive, not available in the primary health care facilities, and not free from complications. Noninvasive serum biomarkers of hepatic fibrosis are the current research focus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess the correlation between serum Chitinase 3-like 1 (CHI3L1) levels and histological severity in patients with Hepatitis B Virus (HBV)-related compensated chronic liver disease (CLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>This cross-sectional study evaluated 50 treatment-na\u00efve patients with chronic hepatitis B with compensated CLD. Liver biopsy was done, and hepatic fibrosis was categorized using the METAVIR scoring system; we divided the study subjects into three groups; group 1 included subjects with F0 and F1, group 2 having F2 group 3 having F3 and F4. Serum CHI3L1 was measured in all by immunoassay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>Among 50 patients, only one had METAVIR score F0, seven had F1, 33 had F2, nine had F3, and none had METAVIR score F4. The median value of CHI3L1 was 460.8 (IQR 340.1-570.3) in all study subjects; 359.5 (IQR 272.8-526.9) in group 1, 450.0 (IQR 307.75-5332.0) in group 2, and 1355.5 (IQR 530.75-1580.5) in the group 3. The difference in median CHI3L1 across the groups was statistically significant. Serum aspartate aminotransferase (AST) and the AST to Platelet Ratio Index (APRI) score had significant positive correlations with CHI3L1 levels. CHI3L1 also had significant positive correlations with METAVIR scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study found a positive correlation between serum CHI3L1 level and hepatic histological severity in patients with HBV-related compensated CLD. Further larger-scale research is needed to establish the fact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1922_20","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T06:18:41Z","timestamp":1619590721000},"page":"1694-1698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of Chitinase 3-like 1 (CHI3L1) as a noninvasive biomarker of hepatic fibrosis in patients with Hepatitis B virus\u2013related compensated chronic liver disease"],"prefix":"10.4103","volume":"10","author":[{"given":"Amit","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABM","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Ruhul","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantanu","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KMJ","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamun","family":"Al Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-34-20240828","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"R2-34-20240828","first-page":"S1","article-title":"Introduction to chronic hepatitis B infection","volume":"101","author":"Wright","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R3-34-20240828","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R4-34-20240828","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R5-34-20240828","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon","year":"2009","journal-title":"Hepatology"},{"key":"R6-34-20240828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5005\/jp-journals-10018-1010","article-title":"Hepatitis B: From Blumberg to Bangladesh","volume":"1","author":"Rahman","year":"2011","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"R7-34-20240828","first-page":"595","article-title":"Epidemiology of hepatitis B virus in Bangladeshi general population","volume":"7","author":"Mahtab","year":"2008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R8-34-20240828","doi-asserted-by":"crossref","first-page":"e68780","DOI":"10.1371\/journal.pone.0068780","article-title":"RDW to platelet ratio: A novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"R9-34-20240828","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/MEG.0b013e32835cb5dd","article-title":"Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection","volume":"25","author":"Ma","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R10-34-20240828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/00365513.2013.773592","article-title":"The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients","volume":"73","author":"Erdogan","year":"2013","journal-title":"Scand J Clin Lab Invest"},{"key":"R11-34-20240828","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","article-title":"Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family","volume":"268","author":"Hakala","year":"1993","journal-title":"J Biol Chem"},{"key":"R12-34-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12026-013-8459-y","article-title":"CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory\/pro-tumorigenic and angiogenic factors","volume":"57","author":"Libreros","year":"2013","journal-title":"Immunol Res"},{"key":"R13-34-20240828","first-page":"172","article-title":"Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer","volume":"53","author":"Johansen","year":"2006","journal-title":"Dan Med Bull"},{"key":"R14-34-20240828","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00042737-200012090-00004","article-title":"Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease","volume":"12","author":"Tran","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R15-34-20240828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0168-8278(03)00184-3","article-title":"Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease","volume":"39","author":"Nojgaard","year":"2003","journal-title":"J Hepatol"},{"key":"R16-34-20240828","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/omi.2015.0037","article-title":"CHI3L1 is a liver-enriched, noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis","volume":"19","author":"Huang","year":"2015","journal-title":"OMICS"},{"key":"R17-34-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"R18-34-20240828","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3109\/00365529709025104","article-title":"Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis?","volume":"32","author":"Johansen","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"R19-34-20240828","doi-asserted-by":"crossref","first-page":"35282","DOI":"10.1038\/srep35282","article-title":"Serum YKL-40 as a marker of liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"6","author":"Kumagai","year":"2016","journal-title":"Sci Rep"},{"key":"R20-34-20240828","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.hbpd.2020.05.009","article-title":"Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China","volume":"19","author":"Jin","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R21-34-20240828","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s15010-018-1136-2","article-title":"Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT","volume":"46","author":"Yan","year":"2018","journal-title":"Infection"},{"key":"R23-34-20240828","doi-asserted-by":"crossref","first-page":"e23200","DOI":"10.1002\/jcla.23200","article-title":"The clinical significance of serum chitinase 3-like 1 in hepatitis B\u2013related chronic liver diseases","volume":"34","author":"Jiang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"R24-34-20240828","doi-asserted-by":"crossref","first-page":"E283","DOI":"10.1111\/hepr.12982","article-title":"Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy","volume":"48","author":"Wang","year":"2018","journal-title":"Hepatol Res"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1922_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:27:06Z","timestamp":1787844426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1922_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1922_20","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}